A Study of the Combination of Oxaliplatin, Capecitabine, and Herceptin (Trastuzumab) And Chemoradiotherapy in The Adjuvant Setting in Operated Patients with HER2+Gastric Or Gastro-Esophageal Junction Cancer (TOXAG Study).

Abali, HuseyinYalcin, SuayibOnal, Huseyin CemDane, FaysalOksuzoglu, BernaOzdemir, NuriyeMertsoylu, HuseyinArtac, MehmetCamci, CelalettinKarabulut, BulentBasal, Fatma BugdayciBudakoglu, BurcinSendur, Mehmet Ali NahitGoktas, BurceOzdener, FatihCalisgan, Arzu2023-06-162023-06-1620160732-183Xhttp://hdl.handle.net/11727/9644enginfo:eu-repo/semantics/closedAccessA Study of the Combination of Oxaliplatin, Capecitabine, and Herceptin (Trastuzumab) And Chemoradiotherapy in The Adjuvant Setting in Operated Patients with HER2+Gastric Or Gastro-Esophageal Junction Cancer (TOXAG Study).conferenceObject344000378109600176